Osmosis Investment Management UK Ltd Purchases Shares of 3,629 Biogen Inc. $BIIB

Osmosis Investment Management UK Ltd purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 3,629 shares of the biotechnology company’s stock, valued at approximately $784,000.

A number of other hedge funds also recently modified their holdings of the business. Reflection Asset Management acquired a new stake in Biogen in the fourth quarter valued at $25,000. Bell Investment Advisors Inc acquired a new position in Biogen during the 2nd quarter worth about $27,000. WFA of San Diego LLC bought a new stake in shares of Biogen in the 2nd quarter valued at about $32,000. Root Financial Partners LLC grew its position in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new stake in shares of Biogen in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Up 0.6%

Shares of Biogen stock opened at $218.12 on Tuesday. The firm has a market cap of $32.23 billion, a PE ratio of 38.61, a P/E/G ratio of 6.75 and a beta of 0.17. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.15. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock has a fifty day moving average price of $205.92 and a 200-day moving average price of $194.87.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current year.

Analyst Ratings Changes

BIIB has been the subject of a number of analyst reports. Citigroup raised their price objective on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Sanford C. Bernstein cut their target price on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Guggenheim raised their price target on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings downgraded Biogen from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, August 12th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $227.07.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.